(Q52184247)

26 April 2018

review article

1 reference

title

Clinical applications of the camptothecins. (English)

1 reference

26 April 2018

author name string

C H Takimoto

series ordinal

1

1 reference

26 April 2018

J Wright

series ordinal

2

1 reference

26 April 2018

S G Arbuck

series ordinal

3

1 reference

26 April 2018

publication date

1 October 1998

1 reference

26 April 2018

number of pages

13

1 reference

Biochimica et Biophysica Acta

inferred from page(s)

published in

1 reference

26 April 2018

volume

1400

1 reference

26 April 2018

issue

1-3

1 reference

26 April 2018

page(s)

107-119

1 reference

26 April 2018

A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Human immunodeficiency virus type 1 reverse transcriptase: enhancement of activity by interaction with cellular topoisomerase I.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Efficacy of camptothecin in progressive multifocal leucoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

The structural basis of camptothecin interactions with human serum albumin: impact on drug stability

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Identification and kinetics of a ?-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I study of CPT-11 and etoposide in patients with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I and pharmacologic study of topotecan in patients with impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase II study of topotecan in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Reduced Albumin Binding Promotes the Stability and Activity of Topotecan in Human Blood

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Conversion of 9-nitro-camptothecin to 9-amino-camptothecin by human blood cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase I study of topotecan for pediatric patients with malignant solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900130-4

7 January 2021

10.1016/S0167-4781(98)00130-4

Identifiers

DOI

1 reference

26 April 2018

1 reference

26 April 2018